Search

Heron Therapeutics Inc

Suletud

SektorTervishoid

0.49

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.48

Max

0.5

Põhinäitajad

By Trading Economics

Sissetulek

-5.2M

-8.1M

Müük

-5.9M

35M

Aktsiakasum

-0.04

Kasumimarginaal

-23.367

Töötajad

128

EBITDA

-6.8M

-7.6M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+300% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

10. aug 2026

Turustatistika

By TradingEconomics

Turukapital

-143M

87M

Eelmine avamishind

0.49

Eelmine sulgemishind

0.49

Uudiste sentiment

By Acuity

50%

50%

155 / 340 Pingereas Healthcare

Heron Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. juuli 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

31. juuli 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

31. juuli 2026, 23:51 UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

31. juuli 2026, 23:46 UTC

News

3M shares declined in after-market trading amid concerns over insider selling by EVP Kevin H. Rhodes, who sold $1.3 million worth of stock.

31. juuli 2026, 23:41 UTC

Social Media
News
Correlated Moves

Goldman Sachs shares declined in after-market trading amid broader market turmoil and hedge fund degrossing linked to losses on leveraged AI investments.

31. juuli 2026, 23:41 UTC

News

JPMorgan Chase & Co. shares are lower in after-market trading following a note highlighting ongoing market rotation and challenges from rising long-term Treasury yields.

31. juuli 2026, 23:36 UTC

News

Carvana shares declined in after-market trading following Citigroup's price target cut to $90, amid broader market weakness from Apple's disappointing guidance.

31. juuli 2026, 23:36 UTC

News

DoorDash Inc shares are lower in after-market trading amid concerns over order demand and rising fuel prices ahead of its upcoming Q2 earnings report.

31. juuli 2026, 23:36 UTC

News

Warner Bros Discovery shares are lower in after-market trading amid concerns over job losses tied to Paramount's $81 billion acquisition and its extended offer deadlines.

31. juuli 2026, 23:36 UTC

News

Bloom Energy Corp shares are lower in after-market trading amid a class action lawsuit alleging securities fraud related to its reliance on Chinese scandium.

31. juuli 2026, 23:32 UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

31. juuli 2026, 23:31 UTC

News

KKR & Co Inc reported record Q2 revenue of $6.31 billion, yet shares are trading lower in after-market hours following earlier volatility.

31. juuli 2026, 23:26 UTC

News

Norwegian Cruise Line shares are lower in after-market hours following Citigroup's price target cut to $22 amid ongoing valuation concerns.

31. juuli 2026, 23:26 UTC

News

NOW Inc shares are higher after market hours, reflecting positive sentiment in the trading companies sector and ongoing demand for energy products.

31. juuli 2026, 23:26 UTC

News

Pomerantz LLP has filed a class action lawsuit against Verra Mobility Corp for securities fraud, contributing to lower after-market trading for the company.

31. juuli 2026, 23:26 UTC

News

Roblox Corp's stock is lower in after-market hours following UBS's price target cut to $45 and a class action lawsuit announcement by Pomerantz LLP.

31. juuli 2026, 23:16 UTC

News

KBR Inc. reported second-quarter revenue of $1.98 billion and reaffirmed full-year guidance, but shares are trading lower in after-market hours.

31. juuli 2026, 23:16 UTC

News

Tractor Supply Co reported second-quarter revenue of $4.54 billion, missing expectations. Shares are trading lower in after-market hours following the earnings release.

31. juuli 2026, 23:16 UTC

News

PBF Energy shares are lower in after-market hours following Citigroup's Neutral rating and price target increase to $74. The stock remains above its 20-day moving average.

31. juuli 2026, 23:16 UTC

News

Huntington Ingalls Industries shares rise in after-market trading following strong Q2 results, with sales of $3.42 billion and a non-GAAP profit of $5.27 per share.

31. juuli 2026, 23:16 UTC

News

Shares of GE Healthcare Technologies are lower in after-market trading following UBS's Neutral rating and a price target increase to $73.

31. juuli 2026, 23:16 UTC

News

Gilead Sciences shares are higher in after-market trading amid market fluctuations. Accessibility challenges for lenacapavir in Latin America may impact potential sales.

31. juuli 2026, 23:16 UTC

News

Alnylam Pharmaceuticals reported Q2 2026 net product revenue of $1.2 billion, driven by strong AMVUTTRA uptake. Shares rose slightly in after-market trading.

31. juuli 2026, 23:11 UTC

News

Lockheed Martin secured a $107.29 million Navy contract for VH-92A rotor blades, with shares trading higher in after-market hours.

31. juuli 2026, 23:06 UTC

News

Hawaiian Electric Industries has signed a 30-year power purchase agreement, with shares trading higher in after-market hours.

31. juuli 2026, 23:06 UTC

News

General Electric Co shares are lower in after-market trading, despite recent analyst upgrades and reaffirmed buy ratings for GE Aerospace.

31. juuli 2026, 23:06 UTC

News

Regeneron Pharmaceuticals shares declined in after-market hours following a class action lawsuit alleging securities fraud related to its Phase III study modifications.

31. juuli 2026, 23:06 UTC

News

Permian Resources Corp shares are trading higher in after-market hours following recognition as a top investment choice by Yahoo Finance, citing strong financial performance.

31. juuli 2026, 23:06 UTC

Social Media
News

NVIDIA shares are lower in after-market trading despite strong fiscal first-quarter results, with revenues of $81.6 billion and record data center sales.

31. juuli 2026, 23:06 UTC

News

Coinbase Global reported a record share of global crypto trading volume but also a significant net loss. Shares are roughly flat in after-market trading.

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

300% tõus

12 kuu keskmine prognoos

Keskmine 2 USD  300%

Kõrge 2 USD

Madal 2 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Heron Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

155 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat